DB17655InvestigationalGene Therapies
ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was... It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.
- Code names
- ABX1100
What you can answer from here — as of July 24, 2025
Which companies are running trials of ABX1100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account